Staar Surgical Gains Key FDA Approval to Broaden Patient Eligibility

NodeGuardian · 2026-02-20T23:15:51+00:00

Staar Surgical's FDA approval extends the age range for its EVO and EVO+ ICLs to 60, increasing patient numbers amid declining laser procedures. The company also shifts leadership after a failed merger, with new interim Co-CEOs leveraging this opportunity.

NodeGuardian

2026-02-20 23:15:51

Abstract generation in progress

Staar Surgical has received a significant FDA approval, expanding the eligible age range for its EVO and EVO+ implantable collamer lenses (ICLs) up to 60 years old. This move substantially increases the potential patient population for the company’s vision correction technology, especially as traditional laser-based procedures decline. The company is also undergoing a leadership transition following a failed merger attempt with Alcon, with new interim Co-CEOs now tasked with capitalizing on this regulatory advantage.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes